Aytu BioPharma Stock
Aytu BioPharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Joshua R. Disbrow
- Employees
- 76
- Market cap
- $22 M
- IPO
- 25/09/2008
- Web
- aytubio.com
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD):…
Aytu BioPharma stock: price history
1D
+1.5%
1W
+0.5%
1M
+3.6%
6M
-21.5%
YTD
-21.5%
1Y
-12.1%
2Y
-10.9%
5Y
-96.2%
10Y
-100.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~19% weaker price swings than usual
Ask the agents about Aytu BioPharma
Analyst assessment of Aytu BioPharma
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 30/09/2026
Aytu BioPharma stock metrics
P/E
-1.49
P/B
0.71
EV/EBITDA
-1.65
RETURN ON EQUITY
-0.0%
NET MARGIN
-0.1%
DEBT/EQUITY
0.51
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.7%
FLOAT SHARES
9,969,502
AVG. DAILY VOLUME (30D)
43,282
Insider transactions (SEC)
Donofrio John Jr.
DOCKERY CARL
JAIN ABHINAV
LIU VIVIAN H
Selhorn Ryan J
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Aytu BioPharma stock
What does Aytu BioPharma do?
Aytu BioPharma, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Joshua R. Disbrow, the company employs around 76 people.
The IPO was on 25/09/2008; the stock trades on NASDAQ under the ticker AYTU.
What do analysts say about Aytu BioPharma stock?
5 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
This is an external assessment, not a statement by Market Jury.
When does Aytu BioPharma report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -19% stronger than usual.
Does Aytu BioPharma pay a dividend?
No, Aytu BioPharma currently does not pay a dividend.
Which stocks are comparable to Aytu BioPharma?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Aytu BioPharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aytu BioPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.